Harrison Gunn is an associate in the firm’s Litigation department. He joined Goodwin in 2020. Harrison focuses his practice on patent matters spanning technologies in the pharmaceutical, electronic and mechanical arts. Harrison also has experience in assisting with Section 337 Investigations at the International Trade Commission. Harrison is a contributor to the firm’s Big Molecule Watch, an award-winning blog that reports real-time analysis and updates on regulatory issues, litigation, legislation, and other news in the developing world of biosimilars.
University of Pennsylvania Law School